Mobile App

Google Play Apple Store
Conference Briefs: Highlighting Myelofibrosis Clinical Data from Key Conferences
Myelofibrosis (MF) is a complex myeloproliferative neoplasm (MPN) that profoundly impacts the lives of patients. Recent years have witnessed advancements in risk stratification, symptom management, and treatment options for patients with MF. Unmet needs include alleviation of limiting thrombocytopenia and anemia, halting disease progression to acute leukemia, and extending survival. This has stimulated the development and investigation of a number of new agents for MF treatment. This Conversations in MF will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).

The activity is supported by downloadable slides that have key discussion and teaching points.
Review the activity and claim AMA/ABS/ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.

Prithviraj Bose, MD Prithviraj Bose, MD
Professor, Department of Leukemia, Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center

John Mascarenhas, MD John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Center of Excellence in Blood Cancers and Myeloid Disorders

Ruben Mesa, MD Ruben Mesa, MD
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Supported by an independent educational grant from
CTI BioPharma Corp., a Sobi Company.

Launch Date: January 17, 2024
Release Date: January 17, 2024
Expiration Date: December 31, 2024

December 31, 2024
Mini Module
Conference Briefs_Myelofibrosis(1730x162).png


Change Settings